Physician profile
Susan Mannan
NPI 1982735437
$7,294.30
in general payments reported to CMS, 2019-2025
31 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $436 · 2021: $788 · 2022: $1,209 · 2023: $1,357 · 2024: $1,207 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,030.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $852.18 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $798.01 | 2019-2025 | |
| Optinose US, INC. | $724.17 | 2019-2025 | |
| Pfizer INC. | $721.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $512.56 | 2019-2024 | Dupixent |
| Csl Behring | $385.03 | 2019-2025 | Hizentra |
| Kaleo, INC. | $354.60 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $239.86 | 2019-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $167.72 | 2020-2023 | |
| Amgen INC. | $149.46 | 2022-2025 | Tezspire |
| Abbvie INC. | $136.87 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $135.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $125.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.34 | 2022-2025 | Cuvitru |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $108.55 | 2022-2025 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $104.15 | 2025 | Neffy |
| Alk-Abello, INC | $97.55 | 2019-2022 | |
| Lilly USA, LLC | $80.10 | 2024-2025 | Ebglyss |
| Pharming Healthcare, INC. | $64.88 | 2024-2025 | Ruconest |
| Incyte Corporation | $59.87 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.52 | 2019-2021 | |
| Leo Pharma INC. | $52.40 | 2022 | |
| Hikma Pharmaceuticals USA | $33.97 | 2023-2024 | Ryaltris |
| Biocryst US Sales Co., LLC | $29.62 | 2024 | Orladeyo |
| Paratek Pharmaceuticals, INC. | $26.99 | 2025 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $26.62 | 2025 | Alvesco |
| Greer Laboratories, INC. | $25.39 | 2025 | Oralair |
| Blueprint Medicines Corporation | $24.02 | 2023 | Ayvakit |
| Shire North American Group INC | $23.35 | 2019 | |
| Aimmune Therapeutics, INC. | $22.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Mannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.